ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

Articles By Pandemic

Using Public Procurement Strategically

The article examines policy decisions and practices in public procurement in India during the pandemic, and finds that bureaucracy could not use public procurement strategically and relied upon archaic and centralised management of procurement to (mis)handle the pandemic. The article also offers some lessons from China’s procurement designs and calls for a major reform in this sector in India.

 

Not ‘Sailing in the Same Boat’: Why the COVID-19 Pandemic Has Been Worse for LGBTQI+ Persons in India

While the COVID-19 pandemic has disrupted lives across the world, there can be no argument that the worst-affected are individuals and communities that were already vulnerable before the pandemic. The pandemic has exacerbated and made visible existing structural inequities. Like other crises, the pandemic is not neutral to gender, caste, ethnicity, class, sexuality or any other determinant of one’s social location.

Making Digital Financial Inclusion a Reality

Technology has had a disruptive effect on the delivery of fi nancial services, and adoption of digital solutions could help accelerate fi nancial inclusion. This article creates a road map for digital fi nancial inclusion in India using the framework based on the eight high-level principles of G-20 nations. While evaluating the progress under each one of these principles, the article concludes with policy recommendations both on supply and demand sides to achieve the coveted digital fi nancial inclusion.

COVID-19 and IPR Waiver

The Government of India is seeking an intellectual property rights waiver under Sections 1 (copyright and related rights), 4 (industrial designs), 5 (patents), and 7 (protection of undisclosed information) of the Agreement on Trade-Related Aspects of Intellectual Property Rights. Seeking an IPR waiver is based on the presumption that it will allow more firms to manufacture vaccines and medicines, thereby enhancing their availability at a cheaper price. However, IPR waivers for COVID-19 vaccines and medicines are unlikely to make any difference. A more effective approach is to use compulsory licences, and reduce tariffs and non-tariff measures.